For example, the FDA (Food and Drug Administration) and the European Medicines Agency approved the proteasome inhibitor Bortezomib for the treatment of multiple myeloma, which also affects the NF-κB pathway 104. This evidence concerns the gene NFKB1 and plasma cell myeloma.